Department of Cardiology, Children's Hospital Boston, Boston, Mass 10032, USA.
Circulation. 2010 Aug 3;122(5):507-16. doi: 10.1161/CIRCULATIONAHA.109.921692. Epub 2010 Jul 19.
Transcatheter pulmonary valve placement is an emerging therapy for pulmonary regurgitation and right ventricular outflow tract obstruction in selected patients. The Melody valve was recently approved in the United States for placement in dysfunctional right ventricular outflow tract conduits.
From January 2007 to August 2009, 136 patients (median age, 19 years) underwent catheterization for intended Melody valve implantation at 5 centers. Implantation was attempted in 124 patients; in the other 12, transcatheter pulmonary valve placement was not attempted because of the risk of coronary artery compression (n=6) or other clinical or protocol contraindications. There was 1 death from intracranial hemorrhage after coronary artery dissection, and 1 valve was explanted after conduit rupture. The median peak right ventricular outflow tract gradient was 37 mm Hg before implantation and 12 mm Hg immediately after implantation. Before implantation, pulmonary regurgitation was moderate or severe in 92 patients (81% with data); no patient had more than mild pulmonary regurgitation early after implantation or during follow-up (>or=1 year in 65 patients). Freedom from diagnosis of stent fracture was 77.8+/-4.3% at 14 months. Freedom from Melody valve dysfunction or reintervention was 93.5+/-2.4% at 1 year. A higher right ventricular outflow tract gradient at discharge (P=0.003) and younger age (P=0.01) were associated with shorter freedom from dysfunction.
In this updated report from the multicenter US Melody valve trial, we demonstrated an ongoing high rate of procedural success and encouraging short-term valve function. All reinterventions in this series were for right ventricular outflow tract obstruction, highlighting the importance of patient selection, adequate relief of obstruction, and measures to prevent and manage stent fracture. Clinical Trial Registration- URL: http://www.clinicaltrials.gov. Unique identifier: NCT00740870.
经导管肺动脉瓣置换术是一种新兴的疗法,用于治疗特定患者的肺动脉瓣反流和右心室流出道梗阻。美敦力公司的 Melody 瓣膜最近在美国获得批准,可用于功能失调的右心室流出道管道。
2007 年 1 月至 2009 年 8 月,5 个中心的 136 名患者(中位年龄 19 岁)接受了旨在进行 Melody 瓣膜植入的导管治疗。在 124 名患者中尝试了植入术;在另外 12 名患者中,由于存在冠状动脉受压的风险(n=6)或其他临床或方案禁忌证,未尝试经导管肺动脉瓣置换术。1 例患者因冠状动脉夹层后颅内出血死亡,1 例患者因管道破裂而取出瓣膜。植入前,右心室流出道的峰值梯度中位数为 37mmHg,植入后立即为 12mmHg。植入前,92 名患者(有数据的患者中 81%)的肺动脉瓣反流为中度或重度;植入后早期或随访期间(65 名患者中至少 1 年)无患者出现轻度以上肺动脉瓣反流。14 个月时,无支架断裂的诊断率为 77.8+/-4.3%。1 年时,无 Melody 瓣膜功能障碍或再次干预的比例为 93.5+/-2.4%。出院时右心室流出道梯度较高(P=0.003)和年龄较小(P=0.01)与较短的无功能障碍时间相关。
在这项来自美国多中心 Melody 瓣膜试验的更新报告中,我们展示了持续较高的手术成功率和令人鼓舞的短期瓣膜功能。本系列中的所有再干预均为右心室流出道梗阻,突出了患者选择、充分缓解梗阻、以及预防和处理支架断裂的重要性。临床试验注册- 网址:http://www.clinicaltrials.gov。独特标识符:NCT00740870。